A Phase One Open-Label Single-Radiolabeled Dose Study to Investigate the Absorption, Metabolism, And Excretion Of [14C] Fruquintinib (HMPL-013) in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 03 Nov 2016
At a glance
- Drugs Fruquintinib (Primary)
- Indications Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Hutchison MediPharma
- 27 Oct 2016 Status changed from recruiting to completed.
- 29 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.
- 29 Aug 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Sep 2016.